Skip to main content

8/12-Day Production of Car-T Cells

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

  • RegistryNCT04186520
  • PhasePhase 1/2
  • StatusRecruiting
  • ConditionNon Hodgkin Lymphoma (NHL)
  • SponsorMedical College of Wisconsin
How 8/12-Day Production of Car-T Cells worksNCT041865201 min

What the film says

Read the transcript

When B-cell lymphoma comes back after CAR T therapy, one common reason is that the cancer drops the target, CD19, from its surface.

The idea: aim at two targets at once, and build the cells faster, in the hospital that treats the patient.

At the Medical College of Wisconsin, a patient's T cells receive a receptor that recognizes both CD19 and CD20. They are grown on site in eight to twelve days, not shipped away for weeks, with interleukin-7 and -15 to keep younger, longer-lasting cells.

In seventeen patients with relapsed mantle cell lymphoma, every one responded, and eighty-eight percent completely.

Nirav Shah leads the trial in Milwaukee, now extending to other lymphomas, CLL, and lymphoma in the brain. Public record; not medical advice.

Sources behind this film

The drug

What is being tested.

A fixed dose of 2.5 x 10^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.

A fixed cryopreserved dose of 2.5 x 10^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.

This is a Phase 1/Phase 2 study. The objectives are as follows: 1. Phase 1: Determine the safety of a fixed dose of 2.5x10^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15 in relapsed refractory B-cell NHL with flexible 8/12-day manufacturing and a fixed 12-day manufacturing process along with an evaluation in chronic lymphocytic leukemia (CLL) and central nervous system (CNS) lymphoma. 2. Phase 1b: Four arms: Arm A: 8/12 flexible manufacturing arm.

The study

How the trial runs.

This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • GENERAL INCLUSION CRITERIA FOR ALL PATIENTS
  • Patients must be aged ≥18 years and ≤80 years with relapsed or refractory B-cell non-Hodgkin Lymphoma.
  • Absolute cluster of differentiation 3 (CD3) count ≥50 mm^3.
  • Magnetic resonance imaging (MRI) brain and lumbar puncture with cerebrospinal fluid (CSF) analysis by cytology and flow cytometry without evidence of central nervous system (CNS) involvement ONLY in patients with history of CNS involvement or clinical suspicion at the time of enrollment EXCEPT Arm E subjects.
  • Measurable disease must be documented within four weeks of the time of consent defined as nodal lesions greater than 15 mm in the long axis or extranodal lesions >10 mm in long and short axis OR bone marrow involvement that is biopsy proven for B-cell NHL (see separate criteria for CLL and primary/secondary CNS lymphoma).
  • Karnofsky performance score ≥70.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.